Status:
TERMINATED
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborating Sponsors:
Canadian Blood Services
Héma-Québec
Conditions:
COVID-19
Eligibility:
All Genders
16+ years
Phase:
PHASE3
Brief Summary
There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains an...
Detailed Description
Problem to be addressed: In December 2019, the Wuhan Municipal Health Committee (Wuhan, China) identified an outbreak of viral pneumonia cases of unknown cause. Coronavirus RNA was quickly identified ...
Eligibility Criteria
Inclusion
- ≥16 years old (\>18 years of age in the United States)
- Admitted to hospital with confirmed COVID-19 respiratory illness
- Receiving supplemental oxygen
- 500 mL of ABO compatible convalescent plasma is available
Exclusion
- Onset of respiratory symptoms \>12 days prior to randomization
- Intubated or plan in place for intubation
- Plasma is contraindicated (e.g. history of anaphylaxis from transfusion)
- Decision in place for no active treatment
Key Trial Info
Start Date :
March 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 16 2021
Estimated Enrollment :
940 Patients enrolled
Trial Details
Trial ID
NCT04348656
Start Date
March 14 2020
End Date
June 16 2021
Last Update
March 3 2022
Active Locations (73)
Enter a location and click search to find clinical trials sorted by distance.
1
Brooklyn Hospital
Brooklyn, New York, United States, 11201
2
Lower Manhattan Hospital
New York, New York, United States, 10038
3
Weill Cornell Medical Center
New York, New York, United States, 10065
4
Hospital Universitário Antônio Pedro (HUAP)
Niterói, Brazil, 24070-035